Form 4: Unity Biotechnology Director Yehia Hashad Acquires 20,000 Stock Options
SEC Form 4 Filing
Director Yehia Hashad acquired 20,000 stock options in Unity Biotechnology, Inc. on March 8, 2025, according to a Form 4 filing.
Summary
- Yehia Hashad, a director of Unity Biotechnology, Inc., acquired 20,000 stock options on March 8, 2025.
- The exercise price of these options is $1.68.
- The options vest in equal monthly installments over 36 months, starting March 8, 2025, and will be fully vested by the third anniversary, contingent on continued service.
- Following the transaction, Hashad directly owns 20,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The acquisition of stock options could be viewed as mildly positive, but it's a routine transaction.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to track the actions of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/08/2025 | Date of earliest transaction and Vesting Commencement Date. |
| 03/07/2035 | Expiration date of the stock options. |
| 03/10/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.